Contrasting bioAffinity Technologies (BIAF) and Its Competitors

bioAffinity Technologies (NASDAQ:BIAF) is one of 38 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare bioAffinity Technologies to related businesses based on the strength of its earnings, profitability, institutional ownership, dividends, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for bioAffinity Technologies and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	48	807	1276	31	2.60

As a group, “Commercial physical research” companies have a potential upside of 6.61%. Given bioAffinity Technologies’ competitors higher possible upside, analysts clearly believe bioAffinity Technologies has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares bioAffinity Technologies and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-2.62
bioAffinity Technologies Competitors	$1.61 billion	$110.50 million	-0.22

bioAffinity Technologies’ competitors have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by insiders. Comparatively, 17.2% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares bioAffinity Technologies and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-165.48%	-17.25%	-10.03%

Volatility & Risk

bioAffinity Technologies has a beta of 3.93, indicating that its stock price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ competitors have a beta of 5.92, indicating that their average stock price is 492% more volatile than the S&P 500.

Summary

bioAffinity Technologies competitors beat bioAffinity Technologies on 9 of the 10 factors compared.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.